Suppr超能文献

同一天输注铁剂与炎症性肠病患者接受生物输注治疗时不良事件发生率增加无关。

Same Day Infusion of Iron Therapy Is Associated With No Increased Risk for Adverse Events Among Patients Receiving Biological Infusions for Inflammatory Bowel Disease.

机构信息

Department of Medicine.

Division of Gastroenterology and Hepatology.

出版信息

J Clin Gastroenterol. 2022 Oct 1;56(9):e318-e322. doi: 10.1097/MCG.0000000000001731. Epub 2022 Jul 22.

Abstract

GOALS

The goal of this study was to compare the relative safety of administering iron infusions on the same day as intravenous (IV) biological therapy to the administration of these treatments on different days in patients with inflammatory bowel disease (IBD).

BACKGROUND

IV iron therapy is often required in patients with IBD. Many patients with IBD who receive IV iron therapy in the outpatient setting also receive biological infusion therapy for treatment of their IBD.

STUDY

Patients with IBD who received IV iron therapy at a single infusion center were included. We compared documented infusion-related reactions in patients with patients receiving an iron infusion on the same day as their biological infusion to those who received their iron infusion on a different day.

RESULTS

Among 481 patients, 129 received an iron infusion on the same day as a biologic infusion. There was no significant difference in the incidence of infusion reaction when comparing patients who received biological infusion therapy in the same session as the iron infusion to those patients who received a biological infusion on a different day (5% vs. 7%, P =0.246) or any IBD-related therapy (5% vs. 8%, P =0.206).

CONCLUSIONS

The frequency and type of infusion reactions in patients receiving IV iron therapy on the same day after IV therapy with biologics was not increased compared with patients who received a biological infusion on a different day. A sequential infusion of biological therapy followed by IV iron therapy may be a safe and cost-effective approach.

摘要

目的

本研究旨在比较在炎症性肠病(IBD)患者中,同日给予静脉(IV)生物治疗与不同日给予这些治疗的相对安全性。

背景

IBD 患者常需要 IV 铁治疗。许多在门诊接受 IV 铁治疗的 IBD 患者也接受 IV 铁治疗用于治疗其 IBD。

研究

纳入在单一输注中心接受 IV 铁治疗的 IBD 患者。我们比较了同一天接受铁输注和不同日接受铁输注的患者记录的输注相关反应。

结果

在 481 例患者中,129 例在同一天接受了铁输注和生物输注。与同一天接受生物输注治疗的患者相比,同一天接受铁输注和生物输注的患者(5% vs. 7%,P=0.246)或任何 IBD 相关治疗(5% vs. 8%,P=0.206)的输注反应发生率无显著差异。

结论

与同一天接受生物输注的患者相比,同日接受 IV 铁治疗的患者的 IV 铁治疗后输注反应的频率和类型并未增加。生物治疗后序贯输注 IV 铁治疗可能是一种安全且具有成本效益的方法。

相似文献

本文引用的文献

4
Safety of Oral and Intravenous Iron.口服和静脉铁剂的安全性。
Acta Haematol. 2019;142(1):8-12. doi: 10.1159/000496966. Epub 2019 Apr 10.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验